TABLE 1.
Randomized controlled study of trimetazidine in heart failure.
| year | study | patients (T/c) | NISH | ISH | LVEF | TMZ (mg/d) | Time | LVEF* | other endpoints | Positive/none |
|---|---|---|---|---|---|---|---|---|---|---|
| 2004 | Thrainsdottir et al. (2004) | 10/9 | 50% | 50% | <40% | 60 | 1 month | 33 ± 8% vs. 37 ± 16% | / | none |
| 2006 | Fragasso et al. (2006b) | 12/12 | / | / | <45% | 60 | 90 days | 34 ± 10% vs. 39 ± 10% | PCr / ATP: 1.80 ± 0.50 vs. 1.35 ± 0.33 | none |
| 2006 | Fragasso et al. (2006a) | 28/27 | / | 100% | <45% | 60 | 13 months | 43 ± 10% vs. 34 ± 7% | / | postive |
| 2007 | Di Napoli et al. (2007) | 30/31 | 34.40% | 100% | <35% | 60 | 48 months | ∼40% vs. ∼30% | / | positive |
| 2008 | Tuunanen et al. (2008) | 12/7 | / | 100% | <40% | 70 | 3 months | 34.8 ± 12% vs. 31.9 ± 12% | / | positive |
| 2009 | Gunes et al. (2009a) | 51/35 | 29% | 66% | <40% | 60 | 3 months | 42.4% ± 6.3% vs. 33.2% ± 6.6% | / | positive |
| 2009 | Gunes et al. (2009b) | 36/36 | / | 33% | <40% | 60 | 6 months | 32.7 ± 6.5% vs. 37.2 ± 5.5% | Max P-wave duration :106.7 ± 15.8 vs. 91.7 ± 12.7 ms | none |
| 2010 | Cera et al. (2010) | 17/13 | / | 60% | <45% | 60 | 6 months | 40.11 ± 1.23% vs. 37.97 ± 13.21%; | QTc interval duration: 451.81 ± 55.02 vs. 453.20 ± 51.50 | positive |
| 2011 | Fragasso et al. (2011) | 25/19 | 34% | 66% | <45% | 60 | 36 months | 42 ± 11% vs.36 ± 6% | REE: 1,580 ± 263 vs. 1,690 ± 337 kcal/day | positive |
| 2014 | Winter et al. (2014) | 30/30 | 100% | 0 | <45% | 70 | 6 months | 31 ± 10% vs. 34 ± 8% | 6MWT: 443 ±25 vs. 506 ±79 m; (18) FDG-PET SUV: 7.0 ±3.6 vs. 8.2±3.4 | none |
| 2016 | Momen et al. (2016) | 55/53 | / | 100% | <40% | 70 | 6 months | 36.6% vs. 31.2% | / | positive |
| 2016 | Jatain et al. (2016) | 52/48 | 46% | / | <45% | 60 | 3 months | 30.9% vs 27% | 6MWT: 402 vs. 349.7 m | positive |
T/c, TMZ/control, trimetazdine group/control group; NISH, non ischemic heart disease; ISH, ischemic heart disease; LVEF, left ventricular ejection fraction stated in the inclusion criteria of the clinical trial, LVEF represents the fact that all patients included in the study had an LVEF < the number indicated; LVEF *, the average LVEF of all patients after treatment, trimetazdine group vs. control group; TMZ, trimetazidine; 6MWT, 6 min walk test; REE, Whole body resting energy expenditure; FDG-PET, β-2-[18 F]-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography; PCr/ATP, phosphocreatine/adenosine triphosphate.